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ABSTRACT 
 
Anti-mycobacterial bioactivity of non polar compounds from red algae Euchema 
spinosum of Barang Lompo Island was studied. A triterpenoid carbocylic  acid has been 
isolated from the chloroform fraction of Euchema spinosum, and its structure was 
determined by spectroscopic evidences including IR and 2D NMR and compared to 
previous data. The isolate was active against Mycobacterium tuberculosis at 
concentration 4 µg/mL, and  could also increase the sensitivity of this pathogen to 
isoniasid drug. These studies suggest that anti-mycobacterial triterpenoid carbocylic  
acid in combination with isoniasid may play an important role in host defence against M. 
tuberculosis strain H37Rv. 
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INTRODUCTION 
 
Tuberculosis is a chronic infectious disease and 
is one of the major enemies of humanity from 
times immemorial. Today it still remains as one 
of the most serious of medical and social 
problems. According to estimation by the World 
Health Organization (WHO), approximately one 
third of the world’s population is infected with 
Mycobacterium tuberculosis, eight million 
people develop tuberculosis disease annually, 
while two million people die and another three 
million new cases are being added each year1 
(WHO, 2008). The advances in the 
chemotherapy of tuberculosis in the last-20th 
century have recently given way to anxiety over 
the evolution of drug resistance based on the 
genetically fixed mutations of M. tuberculosis. 
Moreover, nearly all drugs used for the 
treatment of tuberculosis and possessing 
different mechanisms of activity are able to 
cause adverse side effects on humans2. 
Therefore, it is extremely important to search for 
new, low-toxic substances superior to the 
available drugs in their activity and efficiency. 
This primarily concerns agents possessing 
activity against M. tuberculosis strains with 
multidrug resistance.Modern tuberculosis is 
generally associated with M. tuberculosis and 
M. bovis, mycobacteria that are pathogenic to 
humans. Because of slow growth and 
pathogenicity of M. tuberculosis H37Rv, many 
research groups use fast-growing and/or 
nonpathogenic mycobacteria including M. 
tuberculosis H37Ra, M. smegmatis, M. aurum 
and others as test organisms. A group of 
research works includes investigations on M. 
tuberculosis clinical isolates and strains 
possessing multidrug resistance. Multidrug-
resistant tuberculosis (MDRTB) is strictly 
defined as M. tuberculosis strains showing 
resistance simultaneously against isoniazid and 
rifampicin3,4. Tuberculosis with a different drug 
resistance (DDRTB) involves M. tuberculosis 
strains displaying mono- or polyresistance not 
including associated resistance against 
isoniazid and rifampicin5. Very recently, patterns 
of resistance to commonly used anti-
tuberculosis drugs among  
M. tuberculosis complex isolates from patients 
attending government urban TB diagnostic in 
Makassar, the capital of the South Sulawesi 
Province in Indonesia, was found to be highly 
potential risk factors for MDR-TB6. In order to 
tackle these new situations, it is necessary and 
important to develop not only new treatment 
guidelines, such as combination treatment 
between clinical drug with natural product 
compounds, but also new anti-mycobacterial 
drugs for efficacious clinical control of TB 
patients. On the other hand, the ocean 
environment contains over 80% of world’s plant 
and animal species7 and with more than 
150,000 seaweeds found in the intertidal zones 
and tropical waters of the oceans, it is a primary 
source of natural products8. Research in natural 
products has given a number of drugs and 
recently a novel compound, isolated from 
marine algae was found to be active against 
MDR TB9,10. Considering the potential and 
biodiversity of natural flora in Indonesia  
especially marine algae, it is important to 
explore it for new drug prototypes for 
tuberculosis diseases. In this work, we report for 
the first time the isolation, purification, and 
structural determination of triterpenoid 
carbocylic acid from red algae Euchema 
spinosum. We also tested the activity of 
triterpenoid carbocylic acid alone and in 
combination with the anti-tuberculosis drug 
isoniazid (INH) against M. tuberculosis  strain 
H37Rv (ATCC 27294) to increase sensitivity to 
anti-tuberculosis drugs. 
 
MATERIALS AND METHODS 
 
Materials 
The red algae Euchema spinosum was 
collected in the region of Barang Lompo Island, 
South Sulawesi Province, Indonesian terrestrial. 
Algae  identification was conducted in Marine 
Biology Laboratory Faculty of Natural Sciences 
Hasanuddin University, Indonesia. Chloroform, 
isoniazid, and methanol were purchased from 
Sigma. 
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Extraction and Isolation 
Dry powder of 3.2 kg of algae was macerated 
with MeOH for 72 h, filtered, and solvent 
evaporated to obtain a dark brown extract 
amounting 312 g. The extracts were partitioned 
with chloroform  resulting in 51 g product. The 
chloroform extract was fractionated by VLC and 
produced nine major fractions (I-IX). White 
precipitate found in the third fraction was filtered 
by filtration resulting in 49 mg product. Purity 
test was performed by TLC analysis using three 
solvent systems and its melting point 
determined. 
 
Instrumentation 
The melting point was determined using a micro 
melting point measurement (John Fisher, 
Germany). IR spectra determination was done 
with a Shimadzu  spectrometer (Japan). NMR 
spectra of 1H, 13C and HMBC were obtained 
using a Bruker, Germany DPX-500 
spectrometer at 300 MHz (1H) and 125 MHz 
(13C) with TMS as an external standard. 
Separations and identification of compound 
were conducted with VLC by Merck Si gel 60 
(230-400 mesh), and TLC on aluminum or glass 
plates coated with Merck Si gel 60 F254 and 
thickness of 0.25 mm. 
 
Anti-mycobacterial  activity assays 
For the initial bioactivity screening, standard 
colony assays on Löwenstein-Jensen (LJ) 
medium were performed to assess the anti-
mycobacterial activity of Methanol whole 
extract, chloroform fraction, and compound 1 
with the final concentrations of 10 µg/mL, 
respectively, using the strain M. tuberculosis 
H37Rv (ATCC 27294) and solvent DMSO as 
negative control plus INH as positive control11.  
For testing the anti-mycobacterial activity of 
compound 1 and in combination with isoniasid, 
the strain M. tuberculosis H37Rv (ATCC 27294) 
were grown on Middlebrook 7H19-OADC (oleic 
acid, albumin, dextrose, catalase) (Difco 
Laboratories, USA) at 37 °C for 3 weeks until 
midlog phase. The turbidity of culture were 
adjusted with 7H9 broth to a 0.5 McFarland 
standard using a nephelometer, and cell 
cultures    was   inoculated    on   4   mL   MGIT  
medium12, using solvent (DMSO) as negative 
control, isoniasid  (0.5 and 1.0 µg/mL), and 
combination with compound 1 were indicated. 
Tubes were incubated at 37 °C and inhibition 
growth documented after 3 days; MGIT tubes 
were removed from the incubator and placed on 
a 365 nm UV transilluminator (micro MGIT 
reader). It is important to read the tube every 
day beginning on day 3, until results can be 
interpreted. The growth control tube was 
compared to the positive and negative controls; 
positivity was indicated by bright orange 
fluorescence on the bottom of the tube and an 
orange reflection at the meniscus; negative 
tubes on the other hand showed low level or no 
fluorescence. Once the MGIT growth control is 
positive, the drug-containing tubes will be read 
for interpreting results. The drug-containing 
tubes are interpreted on the same day the MGIT 
GC is positive and for up two additional day, not 
to exceed fourteen days. If the MGIT GC tube is 
not positive by the twelfth day of the test, the 
test is invalid. Interpret the MGIT result as 
Susceptible if the drug-containing tube does not 
fluoresce within two days of onset of 
fluorescence in the GC tube. Interpret the MGIT 
result as resistant if the drug-containing tube 
fluoresces on or within two days of the day of 
onset of fluorescence in the GC tube. When 
interpreting resistance, finalize the result as 
soon as the MGIT GC and the drug-containing 
tubes fluoresce. All inoculated MGIT tubes after 
56 days or negative results should be 
autoclaved prior to disposal. For positive MGIT 
media results should add disinfectant (5 % 
Vesphene) before put in the autoclave bag. 
MGIT tubes are kept in the autoclave bag place 
in the autoclave. After finishing autoclaving, 
send them for the incineration. The growth 
control tube was compared to the positive and 
negative controls; positivity was indicated by 
bright orange fluorescence on the bottom of the 
tube and an orange reflection at the meniscus; 
negative tubes on the other hand showed low 
level or no fluorescence. The assays was 
conducted in duplicates and repeated three 
times to produce representative experimental 
data.  
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RESULTS AND DISCUSSION 
 
The methanol extract of the dried and powdered 
form of red algae Euchema spinosum was 
partitioned with chloroform. The chloroform 
fraction was further separated by silica gel 
chromatography and crystallized to obtain 
compound 1. The compound obtained, 
compound 1 is a white powder crystal, mp 176-
177 oC, giving an indication of triterpenoid  on 
Liebermann-Burchard test.  Its IR spectrum 
showed the absorption bands for hydroxyl 
(1097), aliphatic groups (2962, 2918 and 2850), 
C=C (1635), CH2 (1459), CH3 (1378), C=O 
(1705, 1072) and while strong absorption band 
at 1026 were characterized as a carbocylic acid 
compound11. 
  
Table 1 
1H (300 MHz) and 13C (125 MHz) NMR data of compound 1 in DMSO (TMS) 
 
Carbon Position Carbon  Type δc δH (multiplicity, J (Hz)) 
1 CH2   70.2 3.43 brs 
2 CH2   32.4 1.63 m, 1.82 m 
3 CH2   65.1 4.03 dd 13.1, 4.4 
4 C 42.0  
5 CH 40.1 1.67 m 
6 CH2 17.8 1.13 m 
7 CH2 32.1 1.48 m; 1.17 m 
8 C 40.2  
9 CH 38.4 2.41 dd 8.0, 8.1 
10 C 41.2  
11 CH2 23.5 1.82-1.89 m 
12 CH 123.2 1.78 dd 4.1, 8.2 
13 C 143.7 5.13 s 
14 C 42.4  
15 CH2 26.2  
16 CH2 27.1 2.04 m 
17 C 32.3  
18 CH 46.2 2.00 brd 
19 CH2 40.7 1.28 m; 2.17 dd 3.2,13.2 
20 C 42.5  
21 CH2 30.1 1.79 m 
22 CH2 36.4 1.39 brt, 1.28 dd 
23 CH3 69.8 3.43 d, 9.6; 3.14 d, 9.3 
24 CH3 11.9 0.67 s 
25 CH3 15.8 1.01 s 
26 CH3 17.4 1.04 s 
27 CH3 26.4 1.28 s 
28 COOH 181.3  
29 CH3 28.8 0.89 s 
30 CH3 19.8 1.21 s 
 
 
 
(1) 
Figure 1 
Structure of triterpenoid carbocylic acid (1)  
from red algae Euchema spinosum 
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The 13C NMR and DEPT spectrum exhibited 30 
carbon signals (7×CH3, 11×CH2, 4×CH, 8×C 
including COOH), and  the molecular formula of 
compound 1 was deduced to be C30H46O2. The 
1H NMR spectrum (Table 1) observed the 
presence of seven tertiary methyl groups on 
saturated carbons at d 1.21(s, 3H), 0.89 (s, 6H), 
1.28 (s, 6H), 1.04 (s, 3H), 1.01 (s, 3H), which is 
due to the axial proton attached to C-4 
containing the methyl group, one olefinic proton 
appeared as a double doublet at d 1.78 (dd, 1H, 
J=4.1, 8.2Hz). Two olefinic carbons at d 123.2 
and 143.7 in the 13C NMR (Table 1) spectrum 
indicated that compound 1 belongs to the 
triterpenoid,  and the double bond C=C is at C-
12 and C-13. The position of the carboxylic 
group at C-17 was confirmed by the HMBC 
spectrum (Figure 1). The correlation of C-28 (-
COOH) with H2-16, H-18 and H-22 were 
observed in the HMBC spectrum.  Based on the 
data description above and compared with 
physico-chemical and spectroscopic data of 
previously known compound13, the molecular 
structure of compound 1 is in Figure 1 with 
name of triterpenoid carbocylic acid. In the first, 
antimycobacterial activity of all fractions, 
including compound 1 at concentrations 10 
µg/mL  was measured by incubating with  the  
mycobacterial cells on LJ medium. MeOH 
fraction at concentration 10 µg/mL was able to 
decrease mycobacterial cells growth, where as 
chloroform fraction and compound 1 in the 
same concentration, like INH as positive control 
with no colony growth of M. tuberculosis on LJ 
medium. However, negative control (DMSO) did 
not display  anti-mycobacterial activity (Figure 
2). To confirm this   finding  and  to  identify  the 
MIC value of  
  
 
 
Figure  2 
Effect of  MeOH whole extract, Chloroform Fraction, and Compound  
1 alone on growth inhibition of M. tuberculosis H37Rv (ATCC 27294) 
 strain in Löwenstein-Jensen medium 
 
compound 1,  anti-mycobacterial activity  of this 
compound  against M. tuberculosis  test was 
performed with MGIT medium. The 
combinations of compound 1 and INH were 
tested in the anti-mycobacterial assay described 
above by a checkerboard method in order to 
identify those combinations that could enhance 
bioactivity effect. The anti-mycobacterial activity 
of compound 1 at different concentrations 0, 
0.5, 2, and 4 µg/mL  in combination with INH at 
variation concentrations 0, 0.5, 1 µg/mL  was 
measured by incubating the  mycobacterial cells 
on MGIT medium. Compound 1 alone at 
concentration 0.5 and 2 µg/mL was able to 
decrease mycobacterial cells growth.  
Furthermore, at  concentration 4 µg/mL showed 
significant inhibition of growth of M. tuberculosis 
(Figure 3). This result was in accordance with 
previously reported research by Woldemichael  
et al (2003), where terpenoid compounds from 
Calceolaria pinnifolia (Scrophulariaceae)  
showed  significant inhibition of growth of M. 
tuberculosis with MIC values between 4 and 
128 µg/mL14. 
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Figure 3 
Effect of compound 1 in combination with INH in MGIT medium on growth  
inhibition of M. tuberculosis H37Rv (ATCC 27294) strain.  
(A) Before  placed on a 365 nm UV transilluminator and   
(B) after placed on a 365 nm UV transilluminator 
 
In addition, recently reported research by 
Truong et al (2011), that triterpenoid compound 
from Radermachera boniana  showed 
significant inhibition of growth of M. tuberculosis 
with MIC values 4 µg/mL15. The combinations 
with the INH drug at concentration 0.5 and 1 
µg/mL could completely inhibit the cells at all 
concentration of compound 1, although 
mechanism of anti-mycobacterial  action by 
direct and/or indirect  of triterpenoid  has not 
been clear, but it is speculated that membrane 
disruption of mycobacterial cells by lipophilic 
compounds involves in the mechanism16. 
 
CONCLUSION 
 
 
Compound 1, triterpenoid carbocylic acid  was 
isolated from red algae Euchema spinosum. 
The compound was not only active against M. 
tuberculosis at 4 µg/mL, but also could increase 
the sensitivity of this pathogen to isoniasid drug. 
In conclusion, our results demonstrated that the 
activity isoniasid  drug could be enhanced 
through  triterpenoid  carbocylic acid.  Further 
studies using in vivo methods are required to 
explore the compound responsible for the 
activity and the mechanism of this activity which 
might prove important for improved therapies for 
the treatment and prevention of tuberculosis. 
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